Bruker Q1 Earnings Call Highlights

Bruker beat Q1 expectations with reported revenue of $823.4 million (up 2.7% YoY) though organic revenue declined about 4.4%; non‑GAAP EPS was $0.31 and margins were down year‑over‑year but ahead of forecasts.

Bookings momentum was led by AI‑driven semiconductor metrology, SciY software, and security detection — each delivered >20% organic bookings growth, with semimetrology now a >$300 million annual business (SciY ~$50M, security ~$70M).

Management raised expected cost savings to about $140 million annualized, generated $71 million operating cash flow, paid down $180 million of debt (net leverage 2.9x), and reaffirmed FY26 guidance of $3.57–3.60 billion revenue and $2.10–2.15 non‑GAAP EPS.

Interested in Bruker Corporation? Here are five stocks we like better.

Bruker (NASDAQ:BRKR) reported first-quarter 2026 results that management said came in “well ahead of expectations,” even as the company continued to face pressure from U.S. academic demand weakness as well as tariff and currency headwinds.

President and CEO Frank Laukien told investors that while year-over-year comparisons remained challenging, the company was encouraged by improving order trends. “In the first quarter, our Bruker Scientific Instruments segment or BSI bookings grew organically in the high single digits,” Laukien said, citing strength in industrial research orders and “encouraging double-digit bookings growth year-over-year in academic orders from outside the United States.”

→ 3 Emerging Markets ETFs to Maximize Exposure to High-Potential Countries

Bruker posted first-quarter reported revenue of $823.4 million, up 2.7% year over year. Laukien said foreign exchange provided a 4.5% tailwind and acquisitions contributed 2.6%, which more than offset an organic revenue decline of 4.4%.

On profitability, Laukien said non-GAAP gross margin and operating margin were 50% and 10.2%, respectively, both down year over year but “ahead of expectations.” Non-GAAP diluted EPS was $0.31, down from $0.47 in the prior-year quarter, though Laukien said the result was “meaningfully ahead of our prior expectations.”

→ The Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It Launches

EVP and CFO Gerald Herman attributed margin pressure to multiple factors, including lower volume and mix, foreign exchange, and tariffs. Herman said non-GAAP operating margin declined 250 basis points year over year, reflecting:

350 basis points of headwinds from lower volume and unfavorable mix

170 basis points of headwinds from foreign exchange

30 basis points of headwinds from tariffs

Those pressures were “partially offset by a 300 basis point benefit from our cost-saving actions taken in fiscal year 2025,” Herman said. He added that the company expects year-over-year foreign exchange and tariff headwinds to ease as it laps conditions from the second quarter of 2025.

→ Tyson Foods' Total Returns: Tasty Treats for Income Investors?

On a GAAP basis, diluted EPS was $0.02 versus $0.11 a year earlier, with Herman saying the decline was “mostly due to lease impairment and restructuring charges related to our cost-saving actions.”

Management repeatedly pointed to bookings momentum as a highlight of the quarter. Laukien said Bruker benefited from strong demand in “a few areas more unique to Bruker,” including its AI-driven semiconductor metrology business, the SciY scientific software and lab digitization business, and its European and Middle East security detection business, each delivering organic bookings growth of greater than 20% in the quarter.

Laukien described semiconductor metrology as “now a greater than $300 million annual revenue business,” driven by AI-related demand for memory chips and advanced packaging in the U.S. and Asia-Pacific. He also called out high bandwidth memory as a “big step up more recently,” and said the trend “looks quite durable.”

He also highlighted SciY—about a $50 million revenue business—as benefiting from lab digitization needs in biopharma. “When the Street worries about, well, are they still buying instruments with all this AI? Yes, they're buying instruments, but boy, are they investing in software and digitalization,” Laukien said.

In security detection, Laukien said demand was strong for explosive trace detection systems at airports in Europe and the Middle East, as well as for CBRN detection solutions. He said the security detection business had grown to about $70 million of revenue expected this year.

Asked during Q&A to quantify the impact of these “idiosyncratic growth drivers,” Laukien said they account for “well above 10%,” estimating “more than 10, 12%” of the portfolio.

Laukien and Herman provided detail across Bruker’s instrument groups and BEST segment, with several areas offsetting weaker academic/government spending.

In BioSpin, Laukien said first-quarter revenue was $198 million, with constant-exchange-rate revenue declining in the high single digits. Growth in preclinical imaging systems, SciY software, and services was offset by weakness in NMR systems tied to “soft ACA/GOV performance in China and Europe.” He also noted a year-over-year comparison headwind from an ultra-high field NMR installed in the first quarter of 2025, with “no gigahertz class systems in Q1 of 2026.”

In CALID, first-quarter revenue was $316 million with mid-single-digit constant-currency growth. Laukien said growth was led by molecular spectroscopy and included strength in security detection orders. He added that microbiology and infection diagnostics posted “solid revenue growth,” and in life science mass spectrometry, M&A contributions offset softness in U.S. academic/government. Laukien also called it “encouraging” that life science mass spec orders growth in U.S. academic/government was positive year over year in the quarter.

In Bruker Nano, first-quarter revenue was $246 million with mid-single-digit constant-currency decline. Laukien said strong semiconductor metrology growth was more than offset by weakness in academic/government and industrial markets, though he described orders across Nano as strong, including X-ray industrial research, spatial biology, high bandwidth memory, and advanced packaging metrology.

In the BEST segment, Laukien cited a turnaround driven by superconducting wire and research instruments. He said Bruker received about $80 million of multi-year orders in the first quarter for its research instruments subsidiary tied to fusion energy, and roughly $600 million of multi-year orders over the past five months (December through April) for high-performance superconductors from major MRI customers.

Geographically, Herman said that on an organic basis, Americas and European revenue declined in the low single digits, while Asia-Pacific declined in the low double digits, “driven by a greater 20% decline in revenue performance for China.” He later said first-quarter order performance in China was “solid” and “very encouraging … to see some improvement on a quarter basis.”

Herman said the company generated $71 million of operating cash flow and $47 million of free cash flow in the quarter, an $8 million improvement year over year. Bruker ended the quarter with about $133 million in cash and cash equivalents and paid down $180 million of debt, eliminating a Swiss franc-based term loan. Net leverage declined to 2.9x, he said.

On cost initiatives, Herman said Bruker is now tracking “around $140 million in expected savings on an annualized basis,” above the $100 million to $120 million annualized target previously announced. He said the company cleared most European labor hurdles in the first quarter and expects the majority of savings to be reflected in second-quarter and second-half results. However, he noted that investors “will not see the full $140 million … in the P&L by the end of the year,” with more impact expected as the company moves into 2027.

Despite the first-quarter outperformance, management reaffirmed full-year 2026 guidance. Herman reiterated expectations for:

Reported revenue: $3.57 billion to $3.60 billion (4% to 5% growth)

Organic revenue growth: 1% to 2% (with acquisitions and FX each contributing about 1.5%)

Non-GAAP operating margin expansion: 250 to 300 basis points versus 12.6% in fiscal 2025 (including 300 to 350 basis points of organic expansion, partially offset by ~50 bps FX headwind)

Non-GAAP EPS: $2.10 to $2.15 (15% to 17% growth)

For the second quarter, Herman said Bruker expects organic revenue growth in the low to mid-single digits year over year and anticipates a “meaningful” step up in non-GAAP operating margin and EPS as tariff and foreign exchange headwinds ease. He also said the company has delivered three consecutive quarters of BSI book-to-bill above 1 and expects that to continue.

Laukien said the company chose not to raise guidance, viewing it as “prudent” in a dynamic macro and geopolitical environment and noting higher freight and helium costs as factors. Herman told analysts the company believes it has incorporated variability in energy-related costs into its outlook.

During Q&A, Laukien also discussed leadership changes at BioSpin following the departure of a long-tenured leader, saying he is reorganizing the group and expects to provide more detail on “new group structures by middle of July.”

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker's product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.

The article "Bruker Q1 Earnings Call Highlights" was originally published by MarketBeat.